Video
Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines
Author(s):
Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.
Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant non-small cell lung cancer (NSCLC) will be incorporated into NCCN guidelines. Horn delivered a presentation about the management of EGFR-mutation positive metastatic NSCLC at the 2016 NCCN Annual Conference.
In terms of efficacy, all agents for T790M-mutant disease have elicited response rates around 60%, Horn says. Right now, none of these agents are Category 1 because there aren’t data from large, randomized phase III studies yet.
The difference between these agents, she says, lies in the subtleties in toxicities. With rociletinib, some hyperglycemia has been observed while ASP8273 is associated with hypernatremia. Osimertinib (Tagrisso) has caused rash in some patients.
Horn expects all agents to be included in NCCN guidelines if they are approved.
<<<
